Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InnoCan Pharma ( (TSE:INNO) ) has issued an update.
Innocan Pharma plans to issue a US$450,000 secured debenture to its largest shareholder, Tamar Innovest, bearing 10% annual interest and maturing in 12 months or upon completion of a planned U.S. public offering. Proceeds are earmarked for working capital, NYSE listing costs and general corporate purposes, in a move that bolsters liquidity ahead of a potential U.S. listing and underscores insider support for the company’s capital strategy.
Tamar Innovest, which already owns 17% of Innocan and is managed by company director Ralph Bossino, is participating in a transaction classified as a related-party deal under Canadian securities rules. Innocan will rely on exemptions from formal valuation and minority approval requirements because the debenture’s fair market value is below 25% of its market capitalization, and the financing has been approved by independent directors, signaling governance oversight of the insider funding arrangement.
The most recent analyst rating on (TSE:INNO) stock is a Hold with a C$8.00 price target. To see the full list of analyst forecasts on InnoCan Pharma stock, see the TSE:INNO Stock Forecast page.
Spark’s Take on TSE:INNO Stock
According to Spark, TipRanks’ AI Analyst, TSE:INNO is a Neutral.
The score is weighed down primarily by weak financial performance (ongoing losses and deteriorating cash flow despite strong gross margins and low leverage). Technicals also remain soft with negative MACD and price below key longer-term moving averages. Valuation is only mildly supportive because the negative P/E reflects lack of profitability and no dividend data is available.
To see Spark’s full report on TSE:INNO stock, click here.
More about InnoCan Pharma
Innocan Pharma is an Israel- and Canada-based innovator in the pharmaceuticals and wellness sectors. The company develops a CBD-loaded liposome drug delivery platform for precise, prolonged, non-opioid pain management, and markets a broad portfolio of high-performance self-care and beauty products through its 60%-owned subsidiary BI Sky Global, which focuses on advanced, targeted online sales.
Average Trading Volume: 1,733
Technical Sentiment Signal: Sell
Current Market Cap: C$29.6M
For detailed information about INNO stock, go to TipRanks’ Stock Analysis page.